dc.contributor.author | Ergenç, İlkay | |
dc.contributor.author | Gözaydınoğlu, Büşra | |
dc.contributor.author | Keklikkıran, Çağlayan | |
dc.contributor.author | Yılmaz, Yusuf | |
dc.date.accessioned | 2023-08-18T06:08:49Z | |
dc.date.available | 2023-08-18T06:08:49Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Ergenc, I., Gozaydinoglu, B., Keklikkiran, C., & Yilmaz, Y. (2023). The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. Hepatology forum, 4(2), 69–73. https://doi.org/10.14744/hf.2023.2023.0016 | en_US |
dc.identifier.issn | 1307-5888 | |
dc.identifier.issn | 2757-7392 | |
dc.identifier.uri | https://doi.org/10.14744/hf.2023.2023.0016 | |
dc.identifier.uri | https://hdl.handle.net/11436/8054 | |
dc.description.abstract | Background and Aim: This study investigated the risk of the development of primary biliary cholangitis (PBC) in individuals who were incidentally identified as having positive antimitochondrial antibodies (AMA)-M2.Materials and Methods: We retrospectively reviewed extractable nuclear antibody (ENA) panel test results to identify the incidental AMA-M2 -positive patients. Patients who filled the diagnostic criteria for PBC were excluded. AMA-M2-positive patients were further evaluated by physical examination, liver biochemistry, liver ultrasonography, and transient elas-tography (TE) and were also closely followed.Results: We included 48 (n=45, 93% female) individuals with a median age of 49 (range: 20-69) years. The median follow-up duration was 27 months (range: 9-42) after the detection of AMA-M2. Thirty-three (69%) patients had concomitant autoimmune/inflammatory disorders. Twenty-eight (58%) individuals showed seropositivity for ANA, and 21 had (43%) positive AMA. Fifteen (31%) patients developed typical PBC according to the international PBC diagnostic criteria during the follow-up, and five of them (18%) had significant fibrosis (>= 8.2 kPA) by TE at the time of PBC diagnosis.Conclusion: Two-thirds of the incidental AMA-M2-positive patients devel-oped typical features of PBC after a median 27-month follow-up. Our re-sults suggest that AMA-M2 patients should be closely followed up to detect the late development of PBC | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Kare Publishing | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Anti-mitochondrial M2 antibody | en_US |
dc.subject | AMA-M2 | en_US |
dc.subject | Primary biliary cholangitis | en_US |
dc.subject | Immunoblot | en_US |
dc.title | The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients | en_US |
dc.type | article | en_US |
dc.contributor.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.contributor.institutionauthor | Keklikkıran, Çağlayan | |
dc.contributor.institutionauthor | Yılmaz, Yusuf | |
dc.identifier.doi | 10.14744/hf.2023.2023.0016 | en_US |
dc.identifier.volume | 4 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 69 | en_US |
dc.identifier.endpage | 73 | en_US |
dc.relation.journal | Hepatology Forum | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |